CoronaryAtlas logo
CoronaryAtlas
Angiotensin II
Pathway / Endothelial activation & erosion

Angiotensin II

peptide

Angiotensin II drives endothelial activation, impairs vasodilation, and amplifies plaque inflammation via LOX-1 and NADPH-oxidase signaling.

Pathway placement
Cascade stepEndothelial activation & erosion
Confidencehigh
RationaleVasoconstriction, endothelial dysfunction, LOX-1 upregulation, and pro-inflammatory effects.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
60
A — assay feasibility
66
E — evidence strength
52
T1DI (composite)
9
Specificity differential (R−C)-45
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuren/a
2hypertensive emergencymag 3
2high-demand / peri-operative stressmag 1
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 2
Coverage: 5/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 14 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)
Collection tube
K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Competitive/sandwich immunoassay or LC-MS/MS
Reagent / substrate
Anti-peptide antibody; or isotope-labeled internal standard (MS)
Platform
Immunoassay / LC-MS/MS
Turnaround · availability
Send-out / research · Research-grade

Literature evidence(5)